2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1624

Real-World Insight into the Disease Burden and Treatment of Spondyloarthritis from a US-Based Life Impact Survey

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1328

Recurrent Pericarditis: A Challenge in Autoinflammatory Disease Clinic and the Role of Anakinra

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1223

Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 984

Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1512

Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 989

Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1004

Reevaluating Citrullination and Peptidylarginine Deiminases in Neutrophil Extracellular Trap-like Structures

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1697

Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1616

Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1005

Regulation of Neutrophil Activation in Systemic Lupus Erythematosus

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 988

Regulatory T Cells with Skewed Responses and Propionate-Producing Gut Bacteria Increased Simultaneously in Patients with Relapsing Polychondritis

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1508

Relationship between BMI and Lower Limb Dysfunction in Japanese Female Patients with Rheumatoid Arthritis (the data from NinJa registry)

Rheumatoid Arthritis – Diagnosis, Manifestions, and Outcomes Poster – ARHP

9:00AM-11:00AM: Abstract Number: 1279

Relative Insufficiency of Renal Uric Acid Excretion in Gout Patients with Obesity Leads to High Serum and Glomerular Filtration Load of Uric Acid

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1700

Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1430

Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].